Bruce A. Porter
University of Washington
19 Papers
151 Citations
Bruce A. Porter is an academic researcher from University of Washington. The author has contributed to research in topics: Radioimmunotherapy & Medicine. The author has an hindex of 14, co-authored 19 publications.
Chat about Author
Papers
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support
Oliver W. Press,Janet F. Eary,Frederick R. Appelbaum,Paul J. Martin,Christopher C. Badger,Wil B. Nelp,Stephan D. Glenn,Greg Butchko,Darrell R. Fisher,Bruce A. Porter,Dana C. Matthews,LD Fisher,Irwin D. Bernstein +12 more
TL;DR: High-dose radioimmunotherapy with 131I-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.
748
Magnetic Resonance Imaging of the Bone Marrow in Patients with Leukemia, Aplastic Anemia, and Lymphoma
TL;DR: Magnetic resonance imaging (MRI) of the bone marrow was performed in 29 patients with leukemia, aplastic anemia, or lymphoma who were scheduled for bone marrow transplantation, and in 12 normals.
106
•Journal Article
Magnetic resonance imaging of bone marrow disorders.
TL;DR: MRI can be used to increase diagnostic certainty when a question exists concerning primary or metastatic marrow disease when other imaging studies are inconclusive and chemical shift imaging may further improve the sensitivity and clinical utility of magnetic resonance imaging in patients with hematologic disorders involving the bone marrow.
103
MR imaging of hemorrhagic adnexal masses.
TL;DR: It is concluded that high signal intensity on a Tl-weighted spin echo pulse sequence is evidence for a hemorrhagic mass and that a hematocrit effect appears to be a specific sign for a bleeding cyst.
41
•Journal Article
High Dose Radiolabeled Antibody Therapy of Lymphoma
Irwin D. Bernstein,Janet F. Eary,Christopher C. Badger,Oliver W. Press,FR Appelbaum,Paul J. Martin,Kenneth A. Krohn,Wil B. Nelp,Bruce A. Porter,Darrell R. Fisher,Richard L. Miller,Sherrie Brown,Ronald Levy,E. Donnall Thomas +13 more
TL;DR: T tumor burden and spleen size may determine the feasibility of treatment with radiolabeled antibody in patients with recurrent lymphoma, and studies are being continued to determine the maximal doses of radiation that can be tolerated by nonhematopoietic tissues after infusion of 131I-labeled antibody.
41